论文部分内容阅读
目的评价血必净对消化道恶性肿瘤相关性腹膜炎的临床疗效与安全性。方法入选消化道恶性肿瘤相关性腹膜炎60例,并随机分为试验组28例及对照组32例。对照组给予单纯抗生素治疗,试验组在对照组治疗的基础上予以血必净注射液50 mL,每日2次,疗程7 d,比较治疗前后2组的临床疗效及治疗前后的白细胞计数,C反应蛋白、降钙素原水平、肿瘤坏死因子α、白介素-6水平变化。结果试验组有效率为92.85%,对照组有效率为68.75%,试验组临床症状改善明显。2组患者治疗后较治疗前白细胞计数、C反应蛋白、降钙素原水平、肿瘤坏死因子α、白介素-6水平均显著降低(P<0.05),且试验组用药7 d后上述指标水平均低于对照组(P<0.05)。试验组出现2例皮肤瘙痒,对照组未有明显不良反应。结论血必净对消化道肿瘤相关性腹膜炎在降低白细胞计数、C反应蛋白、肿瘤坏死因子α、降钙素元水平及白介素-6,同时能有效改善患者发热、腹胀、腹痛等不适症状。
Objective To evaluate the clinical efficacy and safety of Xuebijing in the treatment of gastrointestinal malignant tumor-associated peritonitis. Methods Sixty patients with gastrointestinal malignant tumor associated peritonitis were randomly divided into experimental group (n = 28) and control group (n = 32). The control group was treated with antibiotics alone. The experimental group was treated with Xuebijing injection 50 mL twice daily for 7 days. The clinical efficacy and pre and post-treatment white blood cell count, C Reactive protein, procalcitonin levels, tumor necrosis factor alpha, interleukin -6 levels. Results The effective rate of the experimental group was 92.85%, the effective rate of the control group was 68.75%, the clinical symptoms of the experimental group improved significantly. After treatment, the levels of C-reactive protein, procalcitonin, tumor necrosis factor-alpha and interleukin-6 in two groups were significantly lower than those before treatment (P <0.05) Lower than the control group (P <0.05). There were 2 cases of pruritus in the test group and no obvious adverse reactions in the control group. Conclusion Xuebijing on gastrointestinal cancer associated peritonitis in reducing white blood cell count, C-reactive protein, tumor necrosis factor alpha, calcitonin levels and interleukin -6, at the same time can effectively improve patients with fever, bloating, abdominal pain and other symptoms.